Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Breast Cancer

Free Subscription Articles published in Cancer Chemother Pharmacol Retrieve available abstracts of 21 articles: HTML format

Single Articles

January 2026
1. JI X, Yang Y, Ma C, Huang W, et al
   Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.
   Cancer Chemother Pharmacol. 2026;96:15.
   PubMed     Abstract available
   
   
   
2. OHSHIMA S, Araki T, Yashima H, Ishikawa Y, et al
   Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes.
   Cancer Chemother Pharmacol. 2026;96:12.
   PubMed     Abstract available
   
   
   
3. IKEGAMI K, Makihara RA, Katsuya Y, Suzuki T, et al
   Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events.
   Cancer Chemother Pharmacol. 2026;96:3.
   PubMed     Abstract available
   
   
   December 2025
4. SAMBE T, Imamura CK, Hida N, Yamazaki T, et al
   Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer.
   Cancer Chemother Pharmacol. 2025;95:123.
   PubMed     Abstract available
   
   
   
5. CATALANO M, Cekrezi G, De Gennaro Aquino I, Ravizza D, et al
   Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer.
   Cancer Chemother Pharmacol. 2025;95:117.
   PubMed     Abstract available
   
   
   October 2025
6. PIENIAZEK M, Kubeczko M, Las-Jankowska M, Polakiewicz-Gilowska A, et al
   Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety.
   Cancer Chemother Pharmacol. 2025;95:97.
   PubMed     Abstract available
   
   
   June 2025
7. SALAH H, Rabea H, Sheemy MS, Rabie AI, et al
   Targeting insulin-like growth factor-1 (IGF-1) by using metformin in non-diabetic metastatic breast cancer female patients: a randomized controlled trial.
   Cancer Chemother Pharmacol. 2025;95:64.
   PubMed     Abstract available
   
   
   April 2025
8. YUAN L, Zhu Y, Guan G, Liu M, et al
   Napabucasin targets resistant triple negative breast cancer through suppressing STAT3 and mitochondrial function.
   Cancer Chemother Pharmacol. 2025;95:51.
   PubMed     Abstract available
   
   
   December 2024
9. ALANDAG C, Ozturk A, Yulak F, Sahin Inan ZD, et al
   HER-2 SMASH.
   Cancer Chemother Pharmacol. 2024;95:10.
   PubMed     Abstract available
   
   
   November 2024
10. LUO X, Wang N, Xing Y, Gao X, et al
    Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients.
    Cancer Chemother Pharmacol. 2024;94:721-732.
    PubMed     Abstract available
    
    
    August 2024
11. SALINAS-JAZMIN N, Medina-Mondragon MA, Jimenez-Lopez J, Guerrero-Rodriguez SL, et al
    Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter.
    Cancer Chemother Pharmacol. 2024 Aug 24. doi: 10.1007/s00280-024-04701.
    PubMed     Abstract available
    
    
    
12. MARNI R, Malla M, Chakraborty A, Voonna MK, et al
    Combination of ionizing radiation and 2-thio-6-azauridine induces cell death in radioresistant triple negative breast cancer cells by downregulating CD151 expression.
    Cancer Chemother Pharmacol. 2024 Aug 21. doi: 10.1007/s00280-024-04709.
    PubMed     Abstract available
    
    
    
13. CHEN CS, Zirpoli G, Budd GT, Barlow WE, et al
    Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.
    Cancer Chemother Pharmacol. 2024;94:311-321.
    PubMed     Abstract available
    
    
    July 2024
14. YANG D, Xu G, Ding H, Zhong L, et al
    Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer.
    Cancer Chemother Pharmacol. 2024 Jul 31. doi: 10.1007/s00280-024-04702.
    PubMed     Abstract available
    
    
    
15. ISLAM MS, Akter F, Rahman MM, Rafe MR, et al
    Impact of ALDH1A1 and NQO1 gene polymorphisms on the response and toxicity of chemotherapy in Bangladeshi breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Jul 16. doi: 10.1007/s00280-024-04700.
    PubMed     Abstract available
    
    
    
16. MALHI V, Nowicka M, Chen YC, Agarwal P, et al
    UGT1A4 Polymorphism is not Associated with a Clinically Relevant Change in Giredestrant Exposure.
    Cancer Chemother Pharmacol. 2024;94:117-122.
    PubMed     Abstract available
    
    
    June 2024
17. MOEIN A, Jin JY, Wright MR, Wong H, et al
    Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic bre
    Cancer Chemother Pharmacol. 2024 Jun 27. doi: 10.1007/s00280-024-04690.
    PubMed     Abstract available
    
    
    April 2024
18. GHORBANI M, Namazi S, Dehghani M, Razi F, et al
    Gene polymorphisms of TACR1 serve as the potential pharmacogenetic predictors of response to the neurokinin-1 receptor antagonist-based antiemetic regimens: a candidate-gene association study in breast cancer patients.
    Cancer Chemother Pharmacol. 2024 Apr 27. doi: 10.1007/s00280-024-04661.
    PubMed     Abstract available
    
    
    March 2024
19. ZHENG W, Peng W, Qian F, Zhang M, et al
    Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-kappaB signaling and reducing NLRP3 expression in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2024 Mar 8. doi: 10.1007/s00280-024-04660.
    PubMed     Abstract available
    
    
    
20. YUCEL KB, Aydos U, Sutcuoglu O, Kilic ACK, et al
    Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Cancer Chemother Pharmacol. 2024 Mar 4. doi: 10.1007/s00280-024-04641.
    PubMed     Abstract available
    
    
    
21. MITTRA A, Coyne GHOS, Zlott J, Kummar S, et al
    Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
    Cancer Chemother Pharmacol. 2024;93:177-189.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.